Results For "oncology-portfolio"

59 News Found

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

interviews | February 15, 2022

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post

Cosette Pharma acquires rights to Daiichi Sankyo’s eight branded products

Biotech | January 18, 2022

Cosette Pharma acquires rights to Daiichi Sankyo’s eight branded products

As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio

Takeda to acquire Adaptate Biotherapeutics

Biotech | January 11, 2022

Takeda to acquire Adaptate Biotherapeutics

Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System

Sanofi invests US $ 180 mn in Owkin’s AI for oncology pipeline

Biotech | November 26, 2021

Sanofi invests US $ 180 mn in Owkin’s AI for oncology pipeline

Owkin builds best-in-class predictive biomedical AI models and robust data sets

CStone and Jiangsu Hengrui sign exclusive licensing agreement for cancer drugs in China

Biotech | November 22, 2021

CStone and Jiangsu Hengrui sign exclusive licensing agreement for cancer drugs in China

CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region

Aurobindo subsidiary submits MAA for oncology biosimilar

Biotech | September 23, 2021

Aurobindo subsidiary submits MAA for oncology biosimilar

CuraTeQ Biologics is on track for filing a second oncology biosimilar

Sandoz enters agreement for oncology biosimilar medicine bevacizumab

Drug Approval | September 09, 2021

Sandoz enters agreement for oncology biosimilar medicine bevacizumab

Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems

Bayer acquires Noria and PSMA Therapeutics

News | June 07, 2021

Bayer acquires Noria and PSMA Therapeutics

Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)

Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application

News | June 03, 2021

Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application

Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).

Upcoming E-conference

July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Zydus’s acquisition of Assertio to bolster its specialty pharma presence in US market

Alembic Pharma receives USFDA tentative approval for Binimetinib tablets

Manipal Hospitals Mukundapur launches advanced Neuro Biplane Cathlab

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics

Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics

Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics

We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene

We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene

Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited

Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation

Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation

Packaging